Clinical Trial Detail

NCT ID NCT03097328
Title Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

renal cell carcinoma

Therapies

Sapanisertib

Age Groups: adult senior

No variant requirements are available.